Tempting liver fibrosis? long-term psoriatic methotrexate therapy
Methotrexate 17.5. Lable to institutional customers only. For further information visit the Librarian Gateway. Full-text articles are also available through a number of other options: I want to purchase this article Register now Price: US$32 In order to purchase this article you must be a registered user. Register now I want to subscribe to British Dental Journal Select this option to purchase a personal subscription to British Dental Journal. Subscribe now to British Dental Journal I am already a personal subscriber to British Dental Journal Personal subscribers to British Dental Journal can view this article. To do this, you need to associate your subscription with your registration via the My Account page. If you already have an active online subscription, login below to access your account. I am a member of the British Dental Association Members of the British Dental Association receive access to British Dental Journal as part of their membership. Access is available through the British Dental Association web site. Enter your e-mail address and password to login to your nature.com account: Login via Athens E-mail Password Save your password What happens if I save my password? Forgotten your password? You can request this document from a number of document delivery services: British Library Document Supply Center CISTI Canadian Institute for Scientific and Technical Information Infotrieve Thomson ISI Document Delivery You can also request this document from your local library through interlibrary loan services. Return To British Dental Journal Top & 169; 2009 Nature Publishing Group & 8211
 |
|
Treatment of rheumatoid arthritis with methotrexate and
88%2E214%2E192%2E30&clientip=88%2E214%2E192%2E30&usrstatus=&lname=&fname=&email=&autologin=False&insLO=&InstName=&usrid=; path= Cache-control: private Table 1 Table 1 Clinical data of patients Patient Diagnosis rheumatoid factor Sex, age (years) Time of diagnosis Duration of arthritis DMARD Corticosteroids EULAR response criteria TNF staining before treatmenta 1 RA, positive Female, 55 18 years NA Methotrexate 7.5 mg week Prednisolone 5 mg day None 0 2 RA, positive Female, 52 6 years 2 weeks Methotrexate 17.5 mg week Prednisolone 5 mg day Moderate 0 3 RA, positive Female, 58 2 years 6 months Methotrexate 7.5 mg week Prednisolone 7.5 mg day Moderate 1 4 RA, negative Female, 57 4 years 2 weeks Methotrexate 10 mg week None None 0 5 RA, positive Male, 56 9 years 1 month Methotrexate 7.5 mg week Prednisolone 5 mg day Good 1 6 RA, negative Female, 69 1 year 1 year Methotrexate 15 mg week Prednisolon 5 mg day Good 1 7 RA, positive Female, 66 14 years 1 week Methotrexate 10 mg week None Moderate 0 8 RA, positive Female, 66 10 years 3 weeks Methotrexate 12.5 mg week None Moderate 0 9 RA, positive Male, 25 7 months 3 days Methotrexate 17.5 mg day Prednisolon 20-7.5 mg day Moderate 0 10 RA, positive Female, 35 26 years 1 year Methotrexate 17.5 mg day Prednisolon 7.5 mg day Good 1 DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; NA, not available; RA, rheumatoid arthritis.aThe scoring system is described in Materials and methods, Additional immunohistochemical data for patient 10. Lindberg et al. Arthritis Research & Therapy 2006 8:R179 & 160;
 |
